![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 58, Issue 5, 877-886, November 2000
Departments of Biochemistry (D.A.S., W.K.K., B.L.R.), Psychiatry
(B.L.R.), and Neurosciences (B.L.R.), Case Western Reserve University
Medical School, Cleveland, Ohio
Site-directed mutagenesis and molecular modeling were used to
investigate the molecular interactions involved in ligand binding to,
and activation of, the rat 5-hydroxytryptamine2A
(5-HT2A) serotonin (5-HT) receptor. Based on
previous modeling studies utilizing molecular mechanics energy
calculations and molecular dynamics simulations, four sites
(S239[5.43], F240[5.44], F243[5.47], and F244[5.48]) in
transmembrane region V were selected, each predicted to contribute to
agonist and/or antagonist binding. The F243A mutation increased the
affinity of (+/
)4-iodo-2,5-dimethoxyphenylisopropylamine, decreased
the binding of 
-methyl-5HT,
N-
-methyl-5HT, ketanserin, ritanserin, and
spiperone and had no effect on the binding of 5-HT and
5-methyl-N,N-dimethyltryptamine. The F240A mutant had no
effect on the binding of any of the ligands tested, whereas F244A
caused an agonist-specific decrease in binding affinity (3- to
10-fold). S239A caused a 6- to 13-fold decrease in tryptamine-binding affinity and a 5-fold increase in affinity of
4-iodo-2,5-dimethoxyphenylisopropylamine. A subset of the agonists used
in binding studies were used to determine the efficacies and potencies
of these mutants to activate phosphoinositide hydrolysis. The F243A and
F244A mutations reduced agonist stimulated phosphoinositide hydrolysis,
whereas the S239A and F240A mutations had no effect. There was little
correlation between agonist binding and second messenger production.
Furthermore, molecular dynamics simulations, considering these data,
produced ligand-bound structures utilizing substantially different
bonding interactions even among structurally similar ligands (differing by as little as one methyl group). Taken together, these results suggest that relatively minor changes in either receptor or ligand structure can produce drastic and unpredictable changes in both binding
interactions and 5-HT2A receptor activation.
Thus, our finding may have major implications for the future and
feasibility of receptor structure-based drug design.
This article has been cited by other articles:
|
|
 |
|
  S. Ahuja, E. Crocker, M. Eilers, V. Hornak, A. Hirshfeld, M. Ziliox, N. Syrett, P. J. Reeves, H. G. Khorana, M. Sheves, et al. Location of the Retinal Chromophore in the Activated State of Rhodopsin* J. Biol. Chem., April 10, 2009; 284(15): 10190 - 10201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Braden and D. E. Nichols Assessment of the Roles of Serines 5.43(239) and 5.46(242) for Binding and Potency of Agonist Ligands at the Human Serotonin 5-HT2A Receptor Mol. Pharmacol., November 1, 2007; 72(5): 1200 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Moya, K. A. Berg, M. A. Gutierrez-Hernandez, P. Saez-Briones, M. Reyes-Parada, B. K. Cassels, and W. P. Clarke Functional Selectivity of Hallucinogenic Phenethylamine and Phenylisopropylamine Derivatives at Human 5-Hydroxytryptamine (5-HT)2A and 5-HT2C Receptors J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1054 - 1061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Vortherms, P. D. Mosier, R. B. Westkaemper, and B. L. Roth Differential Helical Orientations among Related G Protein-coupled Receptors Provide a Novel Mechanism for Selectivity: STUDIES WITH SALVINORIN A AND THE {kappa}-OPIOID RECEPTOR J. Biol. Chem., February 2, 2007; 282(5): 3146 - 3156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Braden, J. C. Parrish, J. C. Naylor, and D. E. Nichols Molecular Interaction of Serotonin 5-HT2A Receptor Residues Phe339(6.51) and Phe340(6.52) with Superpotent N-Benzyl Phenethylamine Agonists Mol. Pharmacol., December 1, 2006; 70(6): 1956 - 1964. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Setola, M. Dukat, R. A. Glennon, and B. L. Roth Molecular Determinants for the Interaction of the Valvulopathic Anorexigen Norfenfluramine with the 5-HT2B Receptor Mol. Pharmacol., July 1, 2005; 68(1): 20 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Clark, T. E. Dever, J. J. Dever, P. Xu, V. Rehder, M. A. Sosa, and D. J. Baro Arthropod 5-HT2 Receptors: A Neurohormonal Receptor in Decapod Crustaceans That Displays Agonist Independent Activity Resulting from an Evolutionary Alteration to the DRY Motif J. Neurosci., March 31, 2004; 24(13): 3421 - 3435. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. D. Hirst, B. Abrahamsen, F. E. Blaney, A. R. Calver, L. Aloj, G. W. Price, and A. D. Medhurst Differences in the Central Nervous System Distribution and Pharmacology of the Mouse 5-Hydroxytryptamine-6 Receptor Compared with Rat and Human Receptors Investigated by Radioligand Binding, Site-Directed Mutagenesis, and Molecular Modeling Mol. Pharmacol., December 1, 2003; 64(6): 1295 - 1308. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Pauwels and F. C. Colpaert Ca2+ Responses in Chinese Hamster Ovary-K1 Cells Demonstrate an Atypical Pattern of Ligand-Induced 5-HT1A Receptor Activation J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 608 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Ebersole, I. Visiers, H. Weinstein, and S. C. Sealfon Molecular Basis of Partial Agonism: Orientation of Indoleamine Ligands in the Binding Pocket of the Human Serotonin 5-HT2A Receptor Determines Relative Efficacy Mol. Pharmacol., January 1, 2003; 63(1): 36 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Shin, E. Coates, N. J. Murgolo, K. L. Morse, M. Bayne, C. D. Strader, and F. J. Monsma Jr. Molecular Modeling and Site-Specific Mutagenesis of the Histamine-Binding Site of the Histamine H4 Receptor Mol. Pharmacol., July 1, 2002; 62(1): 38 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Manivet, B. Schneider, J. C. Smith, D.-S. Choi, L. Maroteaux, O. Kellermann, and J.-M. Launay The Serotonin Binding Site of Human and Murine 5-HT2B Receptors. MOLECULAR MODELING AND SITE-DIRECTED MUTAGENESIS J. Biol. Chem., May 3, 2002; 277(19): 17170 - 17178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Shapiro, K. Kristiansen, D. M. Weiner, W. K. Kroeze, and B. L. Roth Evidence for a Model of Agonist-induced Activation of 5-Hydroxytryptamine 2A Serotonin Receptors That Involves the Disruption of a Strong Ionic Interaction between Helices 3 and 6 J. Biol. Chem., March 22, 2002; 277(13): 11441 - 11449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ballesteros, L. Shi, and J. A. Javitch Structural Mimicry in G Protein-Coupled Receptors: Implications of the High-Resolution Structure of Rhodopsin for Structure-Function Analysis of Rhodopsin-Like Receptors Mol. Pharmacol., July 1, 2001; 60(1): 1 - 19. [Abstract] [Full Text]
|
|
|
|
|
|
T. Nguyen, D. A. Shapiro, S. R. George, V. Setola, D. K. Lee, R. Cheng, L. Rauser, S. P. Lee, K. R. Lynch, B. L. Roth, et al. Discovery of a Novel Member of the Histamine Receptor Family Mol. Pharmacol., March 1, 2001; 59(3): 427 - 433. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
